Targeting UFMylation in Cancer: Emerging Roles in Cancer Stem Cell Regulation and Therapeutic Targeting
- 1Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka 54, 10000 Zagreb, Croatia
Abstract
UFMylation is an emerging ubiquitin-like post-translational modification involved in protein quality control, endoplasmic reticulum (ER) homeostasis, and cellular responses to stress. Increasing evidence links UFMylation to cancer development and progression, revealing tumor-promoting and tumor-suppressive functions that depend on tumor type, cellular context, and the substrates involved. Recent discoveries also implicated UFMylation in cancer stem cell (CSC) maintenance, particularly through its effects on stemness-associated signaling pathways, transcription factors, tumor sphere formation, and therapeutic resistance. This review outlines the molecular mechanisms and regulation of UFMylation and examines its context-dependent functions in cancer, with particular emphasis on CSC biology. We discuss how alterations in the UFMylation pathway may influence stem-like properties and treatment responses. We also examine therapeutic strategies for targeting the UFMylation pathway, including pharmacological inhibitors, modulation of transcription factors, and combination approaches aimed at improving treatment responses. Particular attention is given to the potential of inducing ferroptosis through UFMylation inhibition as a strategy for targeting CSCs. Finally, this review highlights principal knowledge gaps and future research directions, emphasizing the need to characterize novel relevant substrates, validate observations in physiologically accurate settings, and implement in vivo tumor models to better understand the role of UFMylation in cancer stemness.
Related
- Targeting the MTAP-PRMT5 axis: from synthetic lethality to emerging therapeutic opportunities
- Emerging Therapeutic Strategies for Targeting Hyaluronan in Metabolic Disease from Molecular Design to Clinical Translation
- Editorial: The role of RNA regulation in cancer pathogenesis and therapeutic strategies
- Ubiquitination-Dependent Cyclin Regulation in Gastric Cancer and Emerging Targeted Therapies with Chinese Herbal Bioactive Compounds
- Beyond Mesothelioma: From Diagnostic Biomarker to Therapeutic Opportunity—The Emerging Role of MTAP in Cancer
BibTeX
@article{derfi2026targeting,
title = {{Targeting UFMylation in Cancer: Emerging Roles in Cancer Stem Cell Regulation and Therapeutic Targeting}},
author = {Kristina Vukovic Derfi and Tanja Matijevic Glavan},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272210096},
url = {https://www.mdpi.com/1422-0067/27/22/10096},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeting UFMylation in Cancer: Emerging Roles in Cancer Stem Cell Regulation and Therapeutic Targeting
AU - Kristina Vukovic Derfi
AU - Tanja Matijevic Glavan
PY - 2026
DA - 2026/11/11
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272210096
UR - https://www.mdpi.com/1422-0067/27/22/10096
AB - UFMylation is an emerging ubiquitin-like post-translational modification involved in protein quality control, endoplasmic reticulum (ER) homeostasis, and cellular responses to stress. Increasing evidence links UFMylation to cancer development and progression, revealing tumor-promoting and tumor-suppressive functions that depend on tumor type, cellular context, and the substrates involved. Recent discoveries also implicated UFMylation in cancer stem cell (CSC) maintenance, particularly through its effects on stemness-associated signaling pathways, transcription factors, tumor sphere formation, and therapeutic resistance. This review outlines the molecular mechanisms and regulation of UFMylation and examines its context-dependent functions in cancer, with particular emphasis on CSC biology. We discuss how alterations in the UFMylation pathway may influence stem-like properties and treatment responses. We also examine therapeutic strategies for targeting the UFMylation pathway, including pharmacological inhibitors, modulation of transcription factors, and combination approaches aimed at improving treatment responses. Particular attention is given to the potential of inducing ferroptosis through UFMylation inhibition as a strategy for targeting CSCs. Finally, this review highlights principal knowledge gaps and future research directions, emphasizing the need to characterize novel relevant substrates, validate observations in physiologically accurate settings, and implement in vivo tumor models to better understand the role of UFMylation in cancer stemness.
SN - 1422-0067
ER -